Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Elizabeth Yeu Lin Sells 4,601 Shares of Stock

Key Points

• Insider sale: Elizabeth Yeu Lin sold 4,601 Tarsus Pharmaceuticals shares for approximately $339,830 under a pre-arranged Rule 10b5-1 plan, reducing her holdings by 19.74% to 18,707 shares. She also recently sold an additional 6,977 shares.
• Stock performance: TARS traded at $83.21, near its 12-month high of $85.25, with a market capitalization of approximately $3.65 billion. The company recently reported quarterly revenue above expectations but missed the consensus EPS estimate.
• Analyst outlook: Analysts maintain a “Moderate Buy” consensus rating with an average price target of $90.50, while institutional investors own approximately 90.01% of the company’s shares.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) insider Elizabeth Lin sold 4,601 shares of the company's stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $73.86, for a total value of $339,829.86. Following the completion of the sale, the insider owned 18,707 shares in the company, valued at approximately $1,381,699.02. This represents a 19.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Elizabeth Yeu Lin also recently made the following trade(s):

• On Wednesday, September 2nd, Elizabeth Lin sold 1,590 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $80.00, for a total transaction of $127,200.00.
• On Wednesday, September 2nd, Elizabeth Lin sold 5,387 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $80.00, for a total transaction of $430,960.00.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS stock traded up $0.45 during trading hours on Thursday, hitting $83.21. The company's stock had a trading volume of 733,653 shares, compared to its average volume of 744,913. The company has a 50 day moving average of $65.08 and a 200 day moving average of $65.59. The stock has a market cap of $3.65 billion, a PE ratio of -76.34 and a beta of 0.54. The company has a current ratio of 3.20, a quick ratio of 3.17 and a debt-to-equity ratio of 0.21. Tarsus Pharmaceuticals, Inc. has a 12-month low of $48.20 and a 12-month high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.24). Tarsus Pharmaceuticals had a negative return on equity of 13.53% and a negative net margin of 7.67%.The business had revenue of $173.91 million for the quarter, compared to analysts' expectations of $169.65 million. On average, sell-side analysts forecast that Tarsus Pharmaceuticals, Inc. will post -2.06 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TARS has been the subject of a number of recent research reports. Guggenheim reduced their price objective on Tarsus Pharmaceuticals from $90.00 to $89.00 and set a "buy" rating for the company in a research note on Tuesday, July 21st. Wall Street Zen downgraded Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Sunday, July 12th. Oppenheimer raised their target price on Tarsus Pharmaceuticals from $97.00 to $100.00 and gave the stock an "outperform" rating in a report on Wednesday, August 12th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Tarsus Pharmaceuticals in a research report on Friday, July 17th. Finally, HC Wainwright reissued a "buy" rating and issued a $88.00 price target on shares of Tarsus Pharmaceuticals in a report on Thursday, July 9th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Tarsus Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $90.50.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Tarsus Pharmaceuticals by 5.6% during the fourth quarter. Vanguard Group Inc. now owns 2,399,560 shares of the company's stock valued at $196,476,000 after acquiring an additional 127,470 shares during the last quarter. TimesSquare Capital Management LLC increased its position in shares of Tarsus Pharmaceuticals by 24.3% during the fourth quarter. TimesSquare Capital Management LLC now owns 332,446 shares of the company's stock worth $27,221,000 after purchasing an additional 64,941 shares in the last quarter. Bank of America Corp DE increased its position in shares of Tarsus Pharmaceuticals by 57.5% during the first quarter. Bank of America Corp DE now owns 1,194,377 shares of the company's stock worth $83,786,000 after purchasing an additional 436,271 shares in the last quarter. Ishara Investments LP acquired a new position in Tarsus Pharmaceuticals in the 4th quarter valued at $1,965,000. Finally, Emerald Investment Advisers LLC acquired a new position in Tarsus Pharmaceuticals in the 2nd quarter valued at $3,760,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company's research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus's lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source